Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(CRL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

11/12/2021 | 08:11am EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.



(c) On November 11, 2021, Charles River Laboratories International, Inc. (the "Company") announced that Ms. Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment and Biologics Testing Solutions, will become Chief Operating Officer of the Company, effective immediately, and will add Research Models and Services to her responsibilities. Ms. Girshick will continue to report directly to James C. Foster, Chairman, President and Chief Executive Officer.

Ms. Girshick, age 51, has a proven track record of outstanding performance, leading many of the Company's businesses through important strategic initiatives during her three decades with the Company. Ms. Girshick joined Charles River in 1989 and held positions of increasing responsibility in the Company's Research Models and Services (RMS) Germany and Avian Vaccine Services businesses. In 2010, Ms. Girshick was promoted to Corporate Vice President, Biologics Testing Solutions, followed by a promotion to Corporate Senior Vice President, Research Models and Biologics Testing Solutions in 2013. In 2016, Ms. Girshick assumed responsibility for the Global Discovery Services business. In 2018, Ms. Girshick was promoted to Corporate Executive Vice President overseeing the Discovery, Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services business units. In 2021, she also assumed responsibility for the company's Cell and Gene Therapy CDMO business. In her most recent role, Ms. Girshick was responsible for leading these global businesses, which includes guiding their strategic direction, driving operational excellence and growth, maintaining client and partnership relationships, leading the organization's digital transformation and integrating acquisitions. In this new role, Ms. Girshick will be responsible for leading the RMS, Discovery Services, Safety Assessment, and Biologics Solutions businesses.

Ms. Girshick received a B.A. degree from Eastern Connecticut State University and an M.B.A. degree from the University of Rhode Island. She is also a graduate of the Advanced Management Program at the MIT Sloan School of Management.

The appointment of Ms. Girshick as Corporate Executive Vice President, Chief Operating Officer of the Company was not made pursuant to any arrangement or understanding between her and any other person. Ms. Girshick will receive salary, bonus and equity opportunity, and will participate in other benefit and compensation plans, at levels consistent with her position and scope of responsibility.

On November 11, 2021, the Company issued a press release that discussed the foregoing. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits




(d) Exhibits.



Exhibit No.          Description

99.1                   Press Release of the Company dated November 11, 2021
104                  Cover Page Interactive Data File (embedded within the Inline
                     XBRL document)

© Edgar Online, source Glimpses

All news about CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
01/20Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conferenc..
BU
01/19Charles River Laboratories Partners With Valo Health to Create Drug Discovery, Developm..
MT
01/19Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Ac..
BU
01/19Charles River Laboratories International, Inc and Valo Health Announce Strategic Partne..
CI
01/11Charles River Laboratories Stock Gains Following Upbeat 2022 Outlook
MT
01/11Charles River Laboratories Says Finance Chief David Smith to Retire By End of 2022, Pro..
MT
01/11CHARLES RIVER LABORATORIES INTERNATI : Change in Directors or Principal Officers, Regulati..
AQ
01/11Charles River Laboratories International, Inc. Announces David R. Smith Will Retire as ..
CI
01/11Charles River Laboratories Announces Chief Financial Officer Retirement and Transition ..
BU
01/11Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full ..
CI
More news
Analyst Recommendations on CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
More recommendations
Financials (USD)
Sales 2021 3 522 M - -
Net income 2021 358 M - -
Net Debt 2021 2 484 M - -
P/E ratio 2021 46,4x
Yield 2021 -
Capitalization 16 384 M 16 384 M -
EV / Sales 2021 5,36x
EV / Sales 2022 4,65x
Nbr of Employees 18 400
Free-Float -
Chart CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Duration : Period :
Charles River Laboratories International, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 324,66 $
Average target price 427,08 $
Spread / Average Target 31,5%
EPS Revisions
Managers and Directors
James C. Foster General Counsel
David Ross Smith Chief Financial Officer & Executive Vice President
Arthur C. Hubbs Chief Information Officer & Senior Vice President
Birgit Girshick Chief Operating Officer
Matthew L. Daniel Senior Corporate Counsel
Sector and Competitors
1st jan.Capi. (M$)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.-13.83%16 384
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508